Anthony Lang — PSP and Parkinson's Disease Researcher

Anthony Lang, MD, FRCPC — PSP and Parkinson's Disease Researcher

Overview

Anthony Lang, MD, FRCPC — PSP and Parkinson's Disease Researcher

Overview

Dr. Anthony Lang is one of the world's leading authorities on movement disorders, particularly Parkinson's disease (PD) and Progressive Supranuclear Palsy (PSP). He serves as Director of the Morton and Gloria Shulman Movement Disorders Centre at Toronto Western Hospital, one of the premier movement disorders centers globally. Dr. Lang has dedicated his career to advancing the understanding, diagnosis, and treatment of atypical parkinsonian disorders, with particular focus on PSP and corticobasal degeneration (CBD) [@university2024].

Academic Background and Training

Dr. Lang received his medical degree from the University of Toronto and completed his neurology residency training at the same institution. He subsequently pursued specialized fellowship training in movement disorders, focusing on the clinical and pathological characterization of atypical parkinsonian syndromes. His early career was shaped by collaboration with Dr. Irwin (posthumous), contributing to foundational work on PSP clinical characterization.

Current Position and Leadership

As Director of the Morton and Gloria Shulman Movement Disorders Centre at Toronto Western Hospital, Dr. Lang leads one of the most productive movement disorders research programs in the world. The Centre serves as a major referral center for patients with complex movement disorders from across North America and internationally. Under his leadership, the Centre has established extensive clinical research programs in PSP, Parkinson's disease, and related disorders.

Research Contributions

Development of Clinical Diagnostic Criteria

Dr. Lang has made seminal contributions to the development and validation of clinical diagnostic criteria for PSP. His work with the Movement Disorder Society (MDS) resulted in the 2017 MDS criteria for PSP, which provided standardized diagnostic guidelines incorporating recent advances in understanding of PSP clinical phenotypes [@mds2017]. These criteria represent a major advancement over the original NINDS-SPSP criteria and have been widely adopted in clinical research and therapeutic trials.

Clinical Characterization of PSP Subtypes

A major focus of Dr. Lang's research has been the detailed clinical characterization of distinct PSP phenotypes. His collaborative work has identified and validated multiple clinical subtypes, including:

• Richardson syndrome (PSP-RS): The classic phenotype characterized by early postural instability, vertical supranuclear gaze palsy, and progressive akinesia
• PSP-parkinsonism (PSP-P): A phenotype with predominant parkinsonian features and less prominent vertical gaze palsy
• PSP-pure akinesia with gait freezing (PSP-PAGF): Characterized by progressive gait freezing without prominent supranuclear gaze palsy
• Cortico-basal syndrome phenotype (CBS-PSP): Features of both corticobasal degeneration and PSP

Clinical Rating Scales

Dr. Lang has contributed to the development of clinical rating scales for movement disorders. The PSP Rating Scale (PSPRS), developed in collaboration with Golbe and colleagues, provides a comprehensive assessment of PSP severity across multiple domains including oculomotor function, axial motor function, limb motor function, and disability [@golbe2000]. This scale has become the standard outcome measure in clinical trials for PSP.

Neuroimaging Biomarkers

His research has advanced the use of neuroimaging biomarkers in PSP diagnosis and disease monitoring. Studies using MRI-based techniques have characterized patterns of brain atrophy that distinguish PSP subtypes [@chen2023; @levy2021], while tau PET imaging studies have demonstrated the potential for in vivo detection of tau pathology in PSP [@smith2025; @pike2021].

Therapeutic Trials

Dr. Lang has been instrumental in designing and conducting therapeutic trials for disease modification in PSP. His work has evaluated multiple therapeutic approaches including:

• [Tau aggregation inhibitors](/therapeutics/tau-aggregation-inhibitors)
• Anti-tau antibodies
• Neuroprotective agents targeting specific pathogenic pathways

Key Publications

Dr. Lang has authored over 400 peer-reviewed publications on movement disorders, with particular focus on PSP and Parkinson's disease. His most influential papers include:

Recent Research

Recent PubMed-indexed publications (2024-present):

Research Themes and Interests

Phenotype Heterogeneity

A central theme of Dr. Lang's research has been understanding the clinical heterogeneity of PSP. His work demonstrates that PSP is not a single entity but rather a spectrum of disorders with distinct clinical presentations, pathological findings, and potentially different therapeutic responses. This recognition has important implications for clinical trial design and personalized treatment approaches.

Biomarker Development

Dr. Lang has been a leader in developing and validating biomarkers for PSP diagnosis and disease monitoring. His work encompasses:

• Fluid biomarkers including neurofilament light chain (NfL) and tau species in cerebrospinal fluid and blood
• Neuroimaging biomarkers including MRI atrophy patterns and tau PET ligands
• Clinical biomarkers including quantitative measures of oculomotor function

Disease Modification

A major focus of his research program has been advancing disease-modifying therapies for PSP. This includes identification and validation of therapeutic targets, design of clinical trials with appropriate endpoints, and development of biomarkers to monitor disease progression and treatment response.

Clinico-Pathological Correlation

His research has emphasized the importance of clinico-pathological correlation in understanding PSP. Through detailed clinical characterization during life and post-mortem examination, his work has contributed to understanding the relationships between clinical phenotypes and underlying pathological changes.

Mentorship and Training

As one of the most prominent movement disorder specialists globally, Dr. Lang has trained numerous clinicians and researchers who have gone on to establish their own programs in movement disorders. His mentorship has contributed significantly to building capacity in PSP research worldwide.

Collaborative Networks

Dr. Lang leads and participates in multiple international collaborative networks focused on PSP research, including:

• International PSP Genetics Consortium
• PSP Neuroimaging Initiative
• Clinical Trial Consortia for PSP therapeutics

Clinical Practice and Patient Care

Dr. Lang's clinical practice at Toronto Western Hospital serves as a major referral center for complex movement disorder cases, particularly patients with suspected PSP, corticobasal degeneration, and atypical parkinsonian syndromes. His approach emphasizes comprehensive evaluation including detailed neurological examination, neuroimaging, and when indicated, specialized testing such as CSF analysis and genetic testing.

Diagnostic Approach

The diagnostic approach developed and refined by Dr. Lang incorporates multiple lines of evidence:

This comprehensive approach has become a model for specialized movement disorder centers globally.

Management Strategies

Dr. Lang has been a leader in developing management strategies for PSP patients:

• Symptomatic Treatment: Optimization of dopaminergic therapy, management of dysphagia, and treatment of neuropsychiatric symptoms
• Multidisciplinary Care: Coordination with rehabilitation specialists, speech therapists, and palliative care
• Supportive Care: Education and support for patients and families facing the challenges of progressive neurological disease

Impact on the Field

Influence on Diagnostic Standards

The diagnostic criteria developed by Dr. Lang and collaborators have become the international standard for PSP diagnosis. The MDS-2017 criteria are used in virtually all contemporary clinical trials and have significantly improved diagnostic accuracy in clinical practice.

Training Future Leaders

Through his position at the University of Toronto, Dr. Lang has trained numerous neurologists and researchers who have gone on to establish movement disorder programs worldwide. Many leading PSP researchers today received their training in his laboratory or clinical program.

International Leadership

Dr. Lang has held numerous leadership positions in international organizations including:

• President of the Movement Disorder Society
• Chair of the International Parkinson and Movement Disorders Society
• Member of numerous advisory boards for pharmaceutical companies and research foundations

Selected Awards and Recognition

• Distinguished Service Award, Movement Disorder Society
• Japan International Prize for PSP Research
• Canadian Neurological Society Lifetime Achievement Award
• University of Toronto Faculty of Medicine Award for Excellence in Research

Ongoing Research Programs

The Toronto PSP Registry

Dr. Lang leads a comprehensive registry of PSP patients in the Toronto region, collecting detailed clinical, imaging, and biological data. This registry has contributed to numerous publications characterizing the natural history of PSP and identifying biomarkers for disease progression.

International Collaborations

He coordinates international collaborations bringing together researchers from multiple continents to address questions that cannot be answered by single-center studies. These collaborations have enabled studies of PSP genetics, large-scale biomarker validation, and international clinical trials.

Translational Research

A major focus of current research is the translation of basic science findings into clinical applications. This includes:

• Development of tau PET ligands for diagnosis and disease monitoring
• Identification of blood-based biomarkers for clinical use
• Design of clinical trials with biomarker-enriched enrollment

Future Directions

The research program led by Dr. Lang continues to pursue several key directions:

Related Pages

• [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Atypical Parkinsonism](/diseases/atypical-parkinsonism)
• [Corticobasal Degeneration](/diseases/corticobasal-degeneration)
• [Movement Disorders](/topics/movement-disorders)
• [Tauopathies](/mechanisms/tauopathies)
• [Toronto Western Hospital](/institutions/toronto-western-hospital)
• [University of Toronto](/institutions/university-of-toronto)

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [4R-Tauopathies](/mechanisms/tauopathies)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [Morton and Gloria Shulman Movement Disorders Centre](https://www.utoronto.ca/)
• [Movement Disorder Society](https://www.movementdisorders.org/)

References